UNH vs. HUM: Which Insurance Stock Offers Greater Potential Following CMS's Reversal of Wall Street's Major Medicare Rate Concern?
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 07 2026
0mins
Source: stocktwits
Medicare Advantage Funding Increase: A revised policy is set to add over $13 billion in funding to Medicare Advantage plans, following a previous proposal that significantly impacted insurers' market value.
Stock Performance: Shares of UnitedHealth (UNH) rose by 8% and Humana (HUM) gained 11% after the announcement, although both stocks have seen declines of approximately 45% and 27% respectively over the past year.
Payment Rate Adjustments: The Centers for Medicare & Medicaid Services (CMS) finalized a 2.48% increase in Medicare Advantage payment rates for 2027, reversing earlier proposals that kept rates flat.
Market Sentiment: Retail sentiment for UNH and HUM remains bullish, with analysts providing a range of ratings, indicating a strong outlook for UnitedHealth's expanding AI strategy and potential revenue relief amidst rising medical costs.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy UNH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on UNH
Wall Street analysts forecast UNH stock price to fall
19 Analyst Rating
16 Buy
3 Hold
0 Sell
Strong Buy
Current: 426.540
Low
330.00
Averages
397.82
High
444.00
Current: 426.540
Low
330.00
Averages
397.82
High
444.00
About UNH
UnitedHealth Group Incorporated is a healthcare and well-being company. Its segments include Optum Health, Optum Insight, Optum Rx, and UnitedHealthcare, which includes UnitedHealthcare Employer & Individual, UnitedHealthcare Medicare & Retirement and UnitedHealthcare Community & State. Optum Health provides comprehensive and patient-centered care, addressing the physical, mental, and social well-being. Optum Health delivers primary, specialty and surgical care and helps patients and providers navigate and address complex, chronic and behavioral health needs. Optum Insight connects the healthcare system with services, analytics and platforms that make clinical, administrative and financial processes simpler and more efficient for all participants in the healthcare system. Optum Rx offers a range of pharmacy care services through retail pharmacies, through home delivery, specialty and community health pharmacies and the provision of in-home and community-based infusion services.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
UnitedHealth Group's AI Investment Drives Earnings Growth
- AI Investment Strategy: UnitedHealth Group plans to invest $3 billion in artificial intelligence from 2026 to 2027, with management stating that for every $1 invested, approximately $2 in value is generated, significantly reducing administrative costs and enhancing productivity, thereby strengthening the long-term investment case.
- Efficiency Gains: The company is utilizing AI tools to automate customer service, summarize clinical records, and process administrative requests, expecting to realize returns on investment within 12 to 18 months, which helps address the high-cost issues in the healthcare sector.
- Software Product Development: About one-third of the AI investment is directed towards software products within Optum Insight, aiming to redesign internal workflows, enhance employee productivity, and optimize operational efficiency.
- Strong Financial Performance: In Q1 2026, UnitedHealth generated $111.7 billion in revenue and adjusted earnings of $7.23 per share, both exceeding Wall Street expectations, while also raising full-year earnings guidance to over $18.25 per share, reflecting improved operational performance.
See More
UnitedHealth Group Invests $3 Billion in AI Strategy
- Strategic Investment: UnitedHealth Group plans to invest $3 billion in AI from 2026 to 2027, with management indicating that for every $1 invested, approximately $2 in value is generated, significantly reducing administrative costs and enhancing productivity.
- Efficiency Gains: The company is leveraging AI tools to automate customer service, summarize clinical records, and detect fraud, expecting to realize returns on its investments within 12 to 18 months while further optimizing internal operational workflows.
- Market Performance: In Q1 2026, UnitedHealth generated $111.7 billion in revenue and adjusted earnings of $7.23 per share, both exceeding Wall Street expectations, with management raising full-year earnings guidance to over $18.25 per share, reflecting improved operational performance.
- Competitive Advantage: By reducing administrative expenses and enhancing customer service, UnitedHealth's AI investments not only address cost issues in healthcare but also have the potential to expand margins across multiple business lines, becoming a significant driver of long-term earnings growth.
See More
Congress Members' Stock Trades Draw Investor Attention
- Congressional Trading Trends: Despite Johnson & Johnson's stock rising about 23% this year, Congress members have sold more shares than they bought over the past six months, indicating a cautious stance, with three members investing between $15,000 and $30,000, reflecting differing views on the healthcare sector.
- Healthcare Stock Popularity: UnitedHealth Group's shares have surged over 29%, making it a favored choice among Congress members, with Republican Senator Markwayne Mullin purchasing between $50,001 and $100,000 on February 25, demonstrating strong confidence in the company.
- Investor Caution Advised: While copying congressional trades is a popular trend, the 45-day disclosure period means retail investors often act on stale data, potentially harming their returns as the market has already adjusted to the news by the time they learn of the trades.
- Research First: Investors should view congressional disclosures as a starting point for fundamental research rather than direct buy signals, as both Johnson & Johnson and UnitedHealth Group offer over 2% dividend yields, but investment decisions should be based on current valuations and personal risk tolerance rather than political disclosures.
See More
Congress Members Actively Buy Healthcare Stocks
- Congressional Trading Trends: Rep. Lisa McClain from Michigan and two other lawmakers increased their holdings in Johnson & Johnson in 2023, with McClain purchasing up to $30,000, indicating confidence in the company's future despite other members selling off shares in the past six months.
- Strong Performance of Healthcare Stocks: Johnson & Johnson and UnitedHealth Group have seen their stocks rise approximately 23% and 29% year-to-date, respectively, highlighting their appeal to investors, particularly among congressional members, due to stable earnings growth and high dividend yields.
- Investor Focus on Insider Trading: The stock trades of Congress members are closely monitored by investors because of their roles in shaping policies that affect the healthcare sector; however, explicit insider trading is illegal under the Stock Act, yet these trades can still influence market sentiment.
- Investment Decision Recommendations: While congressional trades may signal confidence, investors should conduct independent research based on current valuations and financial health of the companies rather than relying solely on political disclosures, to avoid potential losses from market volatility.
See More
Healthcare Sector Rally: Raymond James Picks New Stars
- Healthcare Sector Rally: The healthcare sector surged over 6% in June as investors shifted towards defensive plays, reflecting strong interest in healthcare stocks amid poor performance in tech stocks.
- UnitedHealth Group's Strong Performance: UnitedHealth's stock has risen 28%, with expectations for near-term gains from its earnings report on July 16, driven by moderating medical cost trends and improving insurance margins.
- Dividend Growth and Analyst Ratings: UnitedHealth raised its quarterly dividend by 5% to $2.32 per share, with 80% of analysts rating it a buy, although the consensus price target suggests a potential 3% decline over the next year.
- Emerging Opportunities for Janus Living: Janus Living, a newly public company, has seen its stock rise 45% since its IPO, with analysts optimistic about its growth potential in the senior housing market, supporting its future market performance.
See More
Analysis of Schwab U.S. Dividend ETF Investment Strategy
- Clear Investment Strategy: The Schwab U.S. Dividend Equity ETF (SCHD) aims to closely track the Dow Jones U.S. Dividend 100 Index, which screens for companies with higher yields, consistent dividend payments, and strong financial metrics, ensuring investment in 100 high-quality, high-yield dividend stocks.
- Annual Restructuring Optimization: The index undergoes annual screening, recently removing 22 lower-quality stocks and adding 25 new ones, maintaining an average yield of 3.4%, significantly above the S&P 500's 1.1%, while increasing the five-year dividend growth rate to 9.4%.
- Significant Long-term Returns: Since its inception in 2011, the Schwab U.S. Dividend Equity ETF has delivered an annualized total return of 13.3%, demonstrating the strong returns from its concentrated focus on high-yield dividend growth stocks, thus affirming the long-term investment value of dividend growth stocks.
- Diversified Investment Portfolio: By holding the Schwab U.S. Dividend Equity ETF, investors can further diversify their dividend investment portfolios, particularly by adding high-quality dividend stocks in the healthcare sector, such as UnitedHealth Group (UNH), which has consistently paid dividends since 1990 and increased payouts for 16 consecutive years.
See More
UnitedHealth Group's AI Investment Drives Earnings Growth
- AI Investment Strategy: UnitedHealth Group plans to invest $3 billion in artificial intelligence from 2026 to 2027, with management stating that for every $1 invested, approximately $2 in value is generated, significantly reducing administrative costs and enhancing productivity, thereby strengthening the long-term investment case.
- Efficiency Gains: The company is utilizing AI tools to automate customer service, summarize clinical records, and process administrative requests, expecting to realize returns on investment within 12 to 18 months, which helps address the high-cost issues in the healthcare sector.
- Software Product Development: About one-third of the AI investment is directed towards software products within Optum Insight, aiming to redesign internal workflows, enhance employee productivity, and optimize operational efficiency.
- Strong Financial Performance: In Q1 2026, UnitedHealth generated $111.7 billion in revenue and adjusted earnings of $7.23 per share, both exceeding Wall Street expectations, while also raising full-year earnings guidance to over $18.25 per share, reflecting improved operational performance.
See More
UnitedHealth Group Invests $3 Billion in AI Strategy
- Strategic Investment: UnitedHealth Group plans to invest $3 billion in AI from 2026 to 2027, with management indicating that for every $1 invested, approximately $2 in value is generated, significantly reducing administrative costs and enhancing productivity.
- Efficiency Gains: The company is leveraging AI tools to automate customer service, summarize clinical records, and detect fraud, expecting to realize returns on its investments within 12 to 18 months while further optimizing internal operational workflows.
- Market Performance: In Q1 2026, UnitedHealth generated $111.7 billion in revenue and adjusted earnings of $7.23 per share, both exceeding Wall Street expectations, with management raising full-year earnings guidance to over $18.25 per share, reflecting improved operational performance.
- Competitive Advantage: By reducing administrative expenses and enhancing customer service, UnitedHealth's AI investments not only address cost issues in healthcare but also have the potential to expand margins across multiple business lines, becoming a significant driver of long-term earnings growth.
See More
Congress Members' Stock Trades Draw Investor Attention
- Congressional Trading Trends: Despite Johnson & Johnson's stock rising about 23% this year, Congress members have sold more shares than they bought over the past six months, indicating a cautious stance, with three members investing between $15,000 and $30,000, reflecting differing views on the healthcare sector.
- Healthcare Stock Popularity: UnitedHealth Group's shares have surged over 29%, making it a favored choice among Congress members, with Republican Senator Markwayne Mullin purchasing between $50,001 and $100,000 on February 25, demonstrating strong confidence in the company.
- Investor Caution Advised: While copying congressional trades is a popular trend, the 45-day disclosure period means retail investors often act on stale data, potentially harming their returns as the market has already adjusted to the news by the time they learn of the trades.
- Research First: Investors should view congressional disclosures as a starting point for fundamental research rather than direct buy signals, as both Johnson & Johnson and UnitedHealth Group offer over 2% dividend yields, but investment decisions should be based on current valuations and personal risk tolerance rather than political disclosures.
See More
Congress Members Actively Buy Healthcare Stocks
- Congressional Trading Trends: Rep. Lisa McClain from Michigan and two other lawmakers increased their holdings in Johnson & Johnson in 2023, with McClain purchasing up to $30,000, indicating confidence in the company's future despite other members selling off shares in the past six months.
- Strong Performance of Healthcare Stocks: Johnson & Johnson and UnitedHealth Group have seen their stocks rise approximately 23% and 29% year-to-date, respectively, highlighting their appeal to investors, particularly among congressional members, due to stable earnings growth and high dividend yields.
- Investor Focus on Insider Trading: The stock trades of Congress members are closely monitored by investors because of their roles in shaping policies that affect the healthcare sector; however, explicit insider trading is illegal under the Stock Act, yet these trades can still influence market sentiment.
- Investment Decision Recommendations: While congressional trades may signal confidence, investors should conduct independent research based on current valuations and financial health of the companies rather than relying solely on political disclosures, to avoid potential losses from market volatility.
See More
Healthcare Sector Rally: Raymond James Picks New Stars
- Healthcare Sector Rally: The healthcare sector surged over 6% in June as investors shifted towards defensive plays, reflecting strong interest in healthcare stocks amid poor performance in tech stocks.
- UnitedHealth Group's Strong Performance: UnitedHealth's stock has risen 28%, with expectations for near-term gains from its earnings report on July 16, driven by moderating medical cost trends and improving insurance margins.
- Dividend Growth and Analyst Ratings: UnitedHealth raised its quarterly dividend by 5% to $2.32 per share, with 80% of analysts rating it a buy, although the consensus price target suggests a potential 3% decline over the next year.
- Emerging Opportunities for Janus Living: Janus Living, a newly public company, has seen its stock rise 45% since its IPO, with analysts optimistic about its growth potential in the senior housing market, supporting its future market performance.
See More
Analysis of Schwab U.S. Dividend ETF Investment Strategy
- Clear Investment Strategy: The Schwab U.S. Dividend Equity ETF (SCHD) aims to closely track the Dow Jones U.S. Dividend 100 Index, which screens for companies with higher yields, consistent dividend payments, and strong financial metrics, ensuring investment in 100 high-quality, high-yield dividend stocks.
- Annual Restructuring Optimization: The index undergoes annual screening, recently removing 22 lower-quality stocks and adding 25 new ones, maintaining an average yield of 3.4%, significantly above the S&P 500's 1.1%, while increasing the five-year dividend growth rate to 9.4%.
- Significant Long-term Returns: Since its inception in 2011, the Schwab U.S. Dividend Equity ETF has delivered an annualized total return of 13.3%, demonstrating the strong returns from its concentrated focus on high-yield dividend growth stocks, thus affirming the long-term investment value of dividend growth stocks.
- Diversified Investment Portfolio: By holding the Schwab U.S. Dividend Equity ETF, investors can further diversify their dividend investment portfolios, particularly by adding high-quality dividend stocks in the healthcare sector, such as UnitedHealth Group (UNH), which has consistently paid dividends since 1990 and increased payouts for 16 consecutive years.
See More
